Revenue up, profit down
- Consolidated net profit: 9.26 billion rupees, down 26.6 per cent.
- Total revenue: 79.10 billion rupees, up 29.2 per cent.
- Total expenses: up 51 per cent.
- Research and development expenses: up 36.4 per cent.
- Employee benefits expenses: up 33.7 per cent.
Expenses, especially R&D spending, rising faster than revenue suggests the company is accepting lower short-term profits to prepare future products.
Two key markets grow well
Revenue from North America, Zydus' largest market, rose 20.8 per cent to 33.15 billion rupees, aided by higher volumes and new generic drug launches. Revenue from India, its second-largest market, grew 18 per cent, driven by its chronic disease portfolio.
















